open access

Vol 48, No 1 (2017)
Prace oryginalne / Original research articles
Published online: 2017-01-01
Submitted: 2016-08-09
Get Citation

Role of HLA match on results of hematopoietic stem cell transplantations from unrelated donors in children with acute leukemia and bone marrow failure syndromes

Jan Styczyński1, Robert Dębski1, Anna Krenska1, Krzysztof Czyżewski1, Natalia Bartoszewicz1, Ewa Demidowicz1, Ninela Irga-Jaworska2, Elżbieta Drożyńska2, Marcin Płonowski3, Maryna Krawczuk-Rybak3, Tomasz Ociepa4, Tomasz Urasiński4, Mariusz Wysocki1
DOI: 10.1016/j.achaem.2017.01.002
·
Acta Haematol Pol 2017;48(1):48-53.
Affiliations
  1. Katedra i Klinika Pediatrii, Hematologii i Onkologii, Collegium Medicum im. L. Rydygiera w Bydgoszczy, Uniwersytet Mikołaja Kopernika, Szpital Uniwersytecki nr 1 im. Jurasza w Bydgoszczy, Kierownik: prof. dr hab. n. med. Mariusz Wysocki, Poland
  2. Katedra i Klinika Pediatrii, Hematologii i Onkologii, Uniwersytet Medyczny, Kierownik: prof. dr hab. n. med. Elżbieta Adamkiewicz-Drożyńska, Gdańsk, Poland
  3. Klinika Onkologii Dziecięcej, Uniwersytet Medyczny, Kierownik: prof. dr hab. n. med. Maryna Krawczuk-Rybak, Białystok, Poland
  4. Katedra i Klinika Pediatrii, Hematologii i Onkologii, Pomorski Uniwersytet Medyczny, Kierownik: prof. dr hab. n. med. Tomasz Urasiński, Szczecin, Poland

open access

Vol 48, No 1 (2017)
Prace oryginalne / Original research articles
Published online: 2017-01-01
Submitted: 2016-08-09

Abstract

Background

In case of the lack of matched family donors (MFD), hematopoietic stem cell transplantation (HSCT) from unrelated donor (UD) is an established procedure for many acquired and congenital disorders of the hematopoietic system, including malignancies and bone marrow failure (BMF) syndromes.

Objective

The analysis of the results of HSCT in patients with acute leukemia or BMF syndromes from UDs with respect to human leukocyte antigen (HLA) match.

Patients and methods

A total number of 97 of HSCT from UDs performed in single center between 2007 and 2015 in children and adolescents with acute lymphoblastic (ALL) or myeloblastic leukemia (AML) and BMF syndromes were included into this analysis. HLA match between donor and recipient was analyzed at the allele level and classified as 10/10, 9/10 or 8/10. Data were compared to results of 56 MFD-HSCTs. Probability of overall survival (pOS) was given for 3-year and 1-year (as required by JACIE standards) time periods.

Results

The mean survival for all patients estimated by Kaplan–Meier method was 4.8 years (95%CI=4.1–5.5 years). The 3-year pOS after all UD-HSCT was 0,60±0,05, and with respect to 10/10, 9/10 and 8/10 HLA match: 0,61±0,06; 0,59±0,09 and 0,60±0,22, respectively (ns). In patients with AML, 3-year pOS reached 52%, 60% and 60%, respectively. In patients with ALL, 3-year pOS was 73% and 62% (ns) for 10/10 and 9/10 HLA match, respectively, while for BMF syndromes 86% and 57% (ns), respectively.

Conclusion

Current data suggest that results of mismatched and matched UD-HSCT in children with acute leukemia might be comparable.

Abstract

Background

In case of the lack of matched family donors (MFD), hematopoietic stem cell transplantation (HSCT) from unrelated donor (UD) is an established procedure for many acquired and congenital disorders of the hematopoietic system, including malignancies and bone marrow failure (BMF) syndromes.

Objective

The analysis of the results of HSCT in patients with acute leukemia or BMF syndromes from UDs with respect to human leukocyte antigen (HLA) match.

Patients and methods

A total number of 97 of HSCT from UDs performed in single center between 2007 and 2015 in children and adolescents with acute lymphoblastic (ALL) or myeloblastic leukemia (AML) and BMF syndromes were included into this analysis. HLA match between donor and recipient was analyzed at the allele level and classified as 10/10, 9/10 or 8/10. Data were compared to results of 56 MFD-HSCTs. Probability of overall survival (pOS) was given for 3-year and 1-year (as required by JACIE standards) time periods.

Results

The mean survival for all patients estimated by Kaplan–Meier method was 4.8 years (95%CI=4.1–5.5 years). The 3-year pOS after all UD-HSCT was 0,60±0,05, and with respect to 10/10, 9/10 and 8/10 HLA match: 0,61±0,06; 0,59±0,09 and 0,60±0,22, respectively (ns). In patients with AML, 3-year pOS reached 52%, 60% and 60%, respectively. In patients with ALL, 3-year pOS was 73% and 62% (ns) for 10/10 and 9/10 HLA match, respectively, while for BMF syndromes 86% and 57% (ns), respectively.

Conclusion

Current data suggest that results of mismatched and matched UD-HSCT in children with acute leukemia might be comparable.

Get Citation

Keywords

Hematopoietic stem cells; High-dose therapy; Stem cell transplantation; Children; Adolescents and young adults

About this article
Title

Role of HLA match on results of hematopoietic stem cell transplantations from unrelated donors in children with acute leukemia and bone marrow failure syndromes

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 1 (2017)

Pages

48-53

Published online

2017-01-01

DOI

10.1016/j.achaem.2017.01.002

Bibliographic record

Acta Haematol Pol 2017;48(1):48-53.

Keywords

Hematopoietic stem cells
High-dose therapy
Stem cell transplantation
Children
Adolescents and young adults

Authors

Jan Styczyński
Robert Dębski
Anna Krenska
Krzysztof Czyżewski
Natalia Bartoszewicz
Ewa Demidowicz
Ninela Irga-Jaworska
Elżbieta Drożyńska
Marcin Płonowski
Maryna Krawczuk-Rybak
Tomasz Ociepa
Tomasz Urasiński
Mariusz Wysocki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl